Recommendation to temporarily suspend usage of GlaxoSmithKline Rotarix (Rotavirus) vaccine

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration.
• Description:
  Monday, March 22, 2010, 15:54 EDT (03:54 PM EDT)
  
  CDCHAN-00311-2010-03-22-ADV-N
  
  The U.S. Food and Drug Administration (FDA) has learned that DNA from porcine circovirus type 1 (PCV1), a virus not known to cause disease in humans, is present in the Rotarix vaccine. All available evidence indicates that there has been no increased risk to patients who have received this vaccine. PCVI is not known to cause any disease in animals or humans; therefore, it has not been routinely tested for in vaccine development. Rotarix has been extensively studied, before and after approval, and found to have an excellent safety record (i.e., no unusual adverse events). However, FDA is recommending that healthcare practitioners temporarily suspend usage of the Rotarix vaccine for rotavirus immunization in the United States while the agency learns more about the detection of components of the virus found in the vaccine.
  
  
• Subjects:
  Rotavirus Infections/prevention & Control Rotavirus Vaccines
• Source:
  HAN ; 311
• Series:
  Health Alert Network
• Document Type:
  HAN Health Advisory
• Place as Subject:
  United States
• Pages in Document:
  2 unnumbered pages
• Issue:
  311
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:4be4d3b3fd7f555a205fd790999e2beff175cafc9f6566b6120953831fd3cfb2a3bead42c8adbe40a4c6506be54f5e081d462339f963decaa12f691feb881890
• Download URL:
  https://stacks.cdc.gov/view/cdc/25220/cdc_25220_DS1.pdf
• File Type:
  [PDF - 756.82 KB ]